200 related articles for article (PubMed ID: 4076240)
1. The usefulness of bone-marrow scintigraphy in the detection of bone metastasis from prostatic cancer.
Otsuka N; Fukunaga M; Sone T; Yoneda M; Saito N; Tanaka H; Tomomitsu T; Yanagimoto S; Muranaka A; Morita R
Eur J Nucl Med; 1985; 11(8):319-22. PubMed ID: 4076240
[TBL] [Abstract][Full Text] [Related]
2. Bone marrow scintigraphy in the diagnosis of bone metastasis in prostate cancer.
Fuse H; Nagakawa O; Seto H; Katayama T
Int Urol Nephrol; 1994; 26(1):53-61. PubMed ID: 8026923
[TBL] [Abstract][Full Text] [Related]
3. [The usefulness of bone marrow scintigraphy in the detection of bone metastasis from prostatic cancer].
Otsuka N; Fukunaga M; Morita R; Sone T; Yoneda M; Saito N; Tanaka H; Tomomitsu T; Yanagimoto S; Muranaka A
Kaku Igaku; 1985 Feb; 22(2):169-76. PubMed ID: 3159922
[No Abstract] [Full Text] [Related]
4. 99mTc-antigranulocyte bone marrow scintigraphy of breast and prostate skeletal metastases.
Limouris GS; Voliotopoulos V; Stavraka A; Vlahos L
Anticancer Res; 1997; 17(3B):1615-8. PubMed ID: 9179204
[TBL] [Abstract][Full Text] [Related]
5. Intraindividual Comparison of
Rathke H; Afshar-Oromieh A; Giesel FL; Kremer C; Flechsig P; Haufe S; Mier W; Holland-Letz T; De Bucourt M; Armor T; Babich JW; Haberkorn U; Kratochwil C
J Nucl Med; 2018 Sep; 59(9):1373-1379. PubMed ID: 29371410
[TBL] [Abstract][Full Text] [Related]
6. Colloid scintigraphy showing red bone marrow extension in patients with prostatic carcinoma.
Rudberg U; Udén R; Ahlbäck SO
Acta Radiol; 1992 Mar; 33(2):97-102. PubMed ID: 1562417
[TBL] [Abstract][Full Text] [Related]
7. [Bone marrow scintigraphy using radiocolloids in bone metastases. Sensitivity, specificity, reliability and indications].
Fritz P; Adolph J; Bubeck B; Georgi P; zum Winkel K
Rofo; 1986 Jun; 144(6):689-95. PubMed ID: 3012705
[TBL] [Abstract][Full Text] [Related]
8. Technetium-99m-labeled antigranulocyte antibody bone marrow scintigraphy.
Lee KH; Chung JK; Choi CW; Jeong JM; Lee DS; Bang YJ; Lee MC; Kim NK; Koh CS
J Nucl Med; 1995 Oct; 36(10):1800-5. PubMed ID: 7562046
[TBL] [Abstract][Full Text] [Related]
9. Clinical evaluation of the bone marrow imaging agent 99Tcm-phytate in the detection of bone metastases.
Chang CP; Liu RS; Yu SM; Wynchank S; Chu LS; Shiau HY; Cheng TC
Nucl Med Commun; 1996 Dec; 17(12):1030-4. PubMed ID: 9004298
[TBL] [Abstract][Full Text] [Related]
10. Study of the Usefulness of Bone Scan Index Calculated From 99m-Technetium- Hydroxymethylene Diphosphonate (
Higashiyama S; Yoshida A; Kawabe J
Curr Med Imaging; 2021; 17(1):89-96. PubMed ID: 32484112
[TBL] [Abstract][Full Text] [Related]
11. 99mTc-nanocolloid bone marrow scintigraphy in prostatic cancer.
Haddock G; Gray HW; McKillop JH; Bessent RG; Kirk D
Br J Urol; 1989 May; 63(5):497-502. PubMed ID: 2731008
[TBL] [Abstract][Full Text] [Related]
12. Technetium-99m MDP scintigraphy. An insensitive tool for the detection of bone marrow metastases.
Gulenchyn KY; Papoff W
Clin Nucl Med; 1987 Jan; 12(1):45-6. PubMed ID: 3815996
[TBL] [Abstract][Full Text] [Related]
13. Quantitative bone scintigraphy and 24-hour whole-body counting of 99mTc-methylene diphosphonate in patients with prostatic carcinoma.
Sundkvist GM; Ahlgren L; Lilja B; Mattsson S
Nuklearmedizin; 1992 Oct; 31(5):178-81. PubMed ID: 1465355
[TBL] [Abstract][Full Text] [Related]
14. [Bone scintigraphy in bone metastases due to prostatic cancer].
Hidaka H; Ishino Y; Nakayama C; Nakata H; Okamura T
J UOEH; 1987 Dec; 9(4):369-77. PubMed ID: 3438611
[TBL] [Abstract][Full Text] [Related]
15. [New criteria for scintigraphic follow-up of bone metastases following radiotherapy. Results of functional scintigraphy using 99mTc-MDP].
Knop J; Stritzke P; Langendorff G
Nuklearmedizin; 1985 Dec; 24(5-6):238-43. PubMed ID: 4094901
[TBL] [Abstract][Full Text] [Related]
16. Radiotracer imaging in a case of diffuse skeletal hemangiomatosis.
Moore WH; Dhekne RD
Clin Nucl Med; 1981 Sep; 6(9):405-8. PubMed ID: 6456102
[TBL] [Abstract][Full Text] [Related]
17. Discordant findings in patients with non-small-cell lung cancer: absolutely normal bone scans versus disseminated bone metastases on positron-emission tomography/computed tomography.
Ak I; Sivrikoz MC; Entok E; Vardareli E
Eur J Cardiothorac Surg; 2010 Apr; 37(4):792-6. PubMed ID: 20015657
[TBL] [Abstract][Full Text] [Related]
18. Detection of metastatic bone lesions in patients with prostate carcinoma: 99Tcm-monoclonal antibody imaging.
Kiraç S; Duman Y; Cüreklibatur I; Yüksel D; Nazli O; Günaydin G; Taner M
Nucl Med Commun; 1997 Oct; 18(10):968-73. PubMed ID: 9392800
[TBL] [Abstract][Full Text] [Related]
19. Bone marrow scintigraphy in prostatic carcinomas.
Bourgeois P; Malarme M; Van Franck R; Wauters G; Ferremans W
Nucl Med Commun; 1991 Jan; 12(1):35-45. PubMed ID: 2023692
[TBL] [Abstract][Full Text] [Related]
20. Gaucher's disease type 1: assessment of bone involvement by CT and scintigraphy.
Hermann G; Goldblatt J; Levy RN; Goldsmith SJ; Desnick RJ; Grabowski GA
AJR Am J Roentgenol; 1986 Nov; 147(5):943-8. PubMed ID: 3490167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
